COVID-19 Outcomes and Risk Factors for Hospitalization in Adult Patients With Primary Immunodeficiency

Area of Science:

• Immunology
• Infectious Diseases
• Clinical Medicine

Background:

• Primary immunodeficiency (PID) encompasses a group of genetic disorders impairing the immune system's ability to fight infections.
• The clinical impact of coronavirus disease 2019 (COVID-19) on individuals with PID is not fully understood.
• Characterizing COVID-19 outcomes in PID patients is crucial for risk stratification and management.

Purpose of the Study:

• To investigate the clinical features, disease progression, and outcomes of COVID-19 in adult patients diagnosed with primary immunodeficiency.
• To identify potential risk factors associated with severe COVID-19 illness in the PID population.

Main Methods:

• Retrospective analysis of adult PID patients with confirmed COVID-19 infection between March 2020 and August 2022.
• Data collection included institutional records and patient questionnaires.
• Included various PID subtypes such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA).

Main Results:

• 36 adult PID patients were studied; 63.9% managed as outpatients, 36.1% hospitalized, and 19.4% required intensive care.
• The case fatality rate was 8.3%, exceeding that of the general population.
• Risk factors for hospitalization included lymphopenia, elevated inflammatory markers, dyspnea, and prolonged symptom duration.

Conclusions:

• Adults with primary immunodeficiency represent a population at increased risk for severe COVID-19.
• Specific PID subtypes may experience distinct clinical courses and prolonged illness.
• Further research is warranted to optimize care for PID patients during viral pandemics.